SCIENCE - Published Online November 5, 2009 |
Reports - Click here for article.
Submitted on September 3, 2009
Accepted on October 23, 2009
1 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.
2 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.; Present address: Ion Torrent Systems, San Francisco, CA, USA.
3 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.; Present address: San Diego State University, San Diego, CA, USA.
4 Department of Genetics, Harvard Medical School, Cambridge, MA, USA.
5 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.; Present address: Life Technologies, Carlsbad, CA, USA.
6 School of Medicine, Washington University, St. Louis, St. Louis, MO, USA.
* To whom correspondence should be addressed.
Radoje Drmanac , E-mail: rdrmanac@completegenomics.com
Dennis G. Ballinger , E-mail: dballinger@completegenomics.com
Genome sequencing of large numbers of individuals promises to advance the understanding, treatment, and prevention of human diseases, among other applications. We describe a genome sequencing platform that achieves efficient imaging and low reagent consumption with combinatorial probe anchor ligation (cPAL) chemistry to independently assay each base from patterned nanoarrays of self-assembling DNA nanoballs (DNBs). We sequenced three human genomes with this platform, generating an average of 45- to 87-fold coverage per genome and identifying 3.2 to 4.5 million sequence variants per genome. Validation of one genome data set demonstrates a sequence accuracy of about 1 false variant per 100 kilobases. The high-accuracy, affordable cost of $4,400 for sequencing consumables and scalability of this platform enable complete human genome sequencing for the detection of rare variants in large-scale genetic studies.
No comments:
Post a Comment